Daisy Arce, MD
Adult Medicine · Weslaco, TXNPI 1669582789
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,286 of the $9,131 with a category attached, or 79.8%. AstraZeneca accounts for 96.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $4,073 and has fallen 96.0% since, to $162 in 2023. Among adult medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $304.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Lilly USA, LLC$115
- Johnson & Johnson$52
- Radius Health, Inc.$47
- Pfizer$35
- Abbott$19
- plus $28 from 2 others
Across 3 payments — averaging $8375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$25K
What the payments were for
- Consulting fees$7,28680%
- Speaking & faculty fees$3003%
- Travel & lodging$98711%
- Food & beverage$4975%
- Education$611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $8,835 |
| Lilly USA, LLC | 1 | $115 |
| Johnson & Johnson | 3 | $52 |
| Radius Health, Inc. | 3 | $47 |
| Pfizer | 2 | $35 |
| Abbott | 1 | $19 |
| Novo Nordisk | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,131 in reported general payments places this provider in the 90th percentile of 98 adult medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 307 | $307,834 |
| MounjaroTirzepatide | 182 | $219,190 |
| JardianceEmpagliflozin | 153 | $188,446 |
| TradjentaLinagliptin | 114 | $132,336 |
| EliquisApixaban | 100 | $105,372 |
| JanuviaSitagliptin Phosphate | 66 | $82,573 |
| JanumetSitagliptin Phos/Metformin Hcl | 64 | $67,732 |
| FarxigaDapagliflozin Propanediol | 74 | $66,528 |
| MyrbetriqMirabegron | 74 | $60,640 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $42,285 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $42,000 |
| TrulicityDulaglutide | 31 | $40,883 |
| LinzessLinaclotide | 44 | $40,494 |
| ProliaDenosumab | 24 | $40,275 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $37,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $14 | $337,136320 claims |
| Lilly USA, LLCMounjaro, Trulicity | $115 | $260,073213 claims |
| PfizerEliquis | $35 | $105,372100 claims |
| AstraZenecaFarxiga | $8,835 | $66,52874 claims |
| AmgenProlia | $14 | $40,27524 claims |
| Johnson & JohnsonXarelto | $52 | $22,13924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 98 adult medicine providers in Texas.
Other adult medicine in Weslaco
- Deborah HornBellaire$723K
- Thomas MartensPflugerville$87K
- Sakuntalai SrinanthakumarBeaumont$48K
- Francisco Vera AdamesSpring$11K
- Latisha RoweHouston$11K
- Hong XiaoCarrollton$10K
- Mark NovasSheppard Afb$9K
- Jeffory ThomasTexarkana$8K
- Manuel SanchezMcAllen$7K
- Annarosan JoyColleyville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.